Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Guided Therapeutics (GTHP) Return on Sales (2016 - 2025)

Historic Return on Sales for Guided Therapeutics (GTHP) over the last 16 years, with Q3 2025 value amounting to 12.37%.

  • Guided Therapeutics' Return on Sales rose 442400.0% to 12.37% in Q3 2025 from the same period last year, while for Sep 2025 it was 14.79%, marking a year-over-year increase of 418200.0%. This contributed to the annual value of 345.29% for FY2024, which is 3096800.0% down from last year.
  • Latest data reveals that Guided Therapeutics reported Return on Sales of 12.37% as of Q3 2025, which was up 442400.0% from 6.93% recorded in Q2 2025.
  • Guided Therapeutics' 5-year Return on Sales high stood at 3.58% for Q3 2021, and its period low was 2442.0% during Q1 2025.
  • Its 5-year average for Return on Sales is 263.09%, with a median of 57.21% in 2024.
  • Per our database at Business Quant, Guided Therapeutics' Return on Sales skyrocketed by 3318000bps in 2022 and then plummeted by -23750000bps in 2025.
  • Over the past 5 years, Guided Therapeutics' Return on Sales (Quarter) stood at 7.4% in 2021, then crashed by -4414bps to 334.0% in 2022, then surged by 96bps to 12.06% in 2023, then tumbled by -5305bps to 652.0% in 2024, then skyrocketed by 98bps to 12.37% in 2025.
  • Its Return on Sales was 12.37% in Q3 2025, compared to 6.93% in Q2 2025 and 2442.0% in Q1 2025.